70 related articles for article (PubMed ID: 28458369)
1. Evaluation of Maltose-Induced Chemical Degradation at the Interface of Bilayer Tablets.
Matsuzaki N; Yamamoto Y; Murayama D; Katakawa Y; Mimura H; Kimura SI; Iwao Y; Itai S
Chem Pharm Bull (Tokyo); 2017; 65(5):478-486. PubMed ID: 28458369
[TBL] [Abstract][Full Text] [Related]
2. Physicochemical properties and drug-release mechanisms of dual-release bilayer tablet containing mirabegron and fesoterodine fumarate.
Lee HG; Park YS; Jeong JH; Kwon YB; Shin DH; Kim JY; Rhee YS; Park ES; Kim DW; Park CW
Drug Des Devel Ther; 2019; 13():2459-2474. PubMed ID: 31413543
[No Abstract] [Full Text] [Related]
3. Solution degradant of mirabegron extended release tablets resulting from a Strecker-like reaction between mirabegron, minute amounts of hydrogen cyanide in acetonitrile, and formaldehyde in PEG during sample preparation.
Lin J; Huang T; Feng M; Li D; Zhao D; Wang J; Jin J; Zhu W; Li M
J Pharm Biomed Anal; 2019 May; 168():181-188. PubMed ID: 30818256
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of trace amorphous solifenacin succinate in pharmaceutical formulations by transmission Raman spectroscopy.
Terada H; Hattori Y; Sasaki T; Otsuka M
Int J Pharm; 2019 Jun; 565():325-332. PubMed ID: 31075440
[TBL] [Abstract][Full Text] [Related]
5. Preparative isolation and high-resolution mass identification of 10 stressed study degradants of nicorandil tablets.
Prakash L; Malipeddi H; Subbaiah BV
J Chromatogr Sci; 2015 Jan; 53(1):122-6. PubMed ID: 24837014
[TBL] [Abstract][Full Text] [Related]
6. Correlating bilayer tablet delamination tendencies to micro-environmental thermodynamic conditions during pan coating.
Zacour BM; Pandey P; Subramanian G; Gao JZ; Nikfar F
Drug Dev Ind Pharm; 2014 Jun; 40(6):829-37. PubMed ID: 23638984
[TBL] [Abstract][Full Text] [Related]
7. Identification of low-level degradants from low dose tablets.
Blanchard A; Lee C; Nickerson B; Lohr LL; Jensen AJ; Alsante KM; Sharp TR; Santafianos DP; Morris R; Snyder KD
J Pharm Biomed Anal; 2004 Oct; 36(2):265-75. PubMed ID: 15496319
[TBL] [Abstract][Full Text] [Related]
8. Influence of compaction properties and interfacial topography on the performance of bilayer tablets.
Kottala N; Abebe A; Sprockel O; Akseli I; Nikfar F; Cuitiño AM
Int J Pharm; 2012 Oct; 436(1-2):171-8. PubMed ID: 22728259
[TBL] [Abstract][Full Text] [Related]
9. Comparison of breaking tests for the characterization of the interfacial strength of bilayer tablets.
Castrati L; Mazel V; Busignies V; Diarra H; Rossi A; Colombo P; Tchoreloff P
Int J Pharm; 2016 Nov; 513(1-2):709-716. PubMed ID: 27717917
[TBL] [Abstract][Full Text] [Related]
10. Solid state compatibility studies with tablet excipients using non thermal methods.
Liltorp K; Larsen TG; Willumsen B; Holm R
J Pharm Biomed Anal; 2011 Jun; 55(3):424-8. PubMed ID: 21411259
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
12. Multiple-layer compression-coated tablets: formulation and humidity studies of novel chewable amoxicillin/clavulanate tablet formulations.
Wardrop J; Jaber AB; Ayres JW
Drug Dev Ind Pharm; 1998 Aug; 24(8):729-36. PubMed ID: 9876520
[TBL] [Abstract][Full Text] [Related]
13. An active film-coating approach to enhance chemical stability of a potent drug molecule.
Desai D; Rao V; Guo H; Li D; Stein D; Hu FY; Kiesnowski C
Pharm Dev Technol; 2012; 17(2):227-35. PubMed ID: 21073265
[TBL] [Abstract][Full Text] [Related]
14. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
15. Development of a new test for the easy characterization of the adhesion at the interface of bilayer tablets: proof-of-concept study by experimental design.
Busignies V; Mazel V; Diarra H; Tchoreloff P
Int J Pharm; 2014 Dec; 477(1-2):476-84. PubMed ID: 25445527
[TBL] [Abstract][Full Text] [Related]
16. Stability-indicating UHPLC method for determination of nevirapine in its bulk form and tablets: identification of impurities and degradation kinetic study.
Reis NF; de Assis JC; Fialho SL; Pianetti GA; Fernandes C
J Pharm Biomed Anal; 2016 Jul; 126():103-8. PubMed ID: 27179642
[TBL] [Abstract][Full Text] [Related]
17. Stability of amlodipine besylate and atenolol in multi-component tablets of mono-layer and bi-layer types.
Aryal S; Skalko-Basnet N
Acta Pharm; 2008 Sep; 58(3):299-308. PubMed ID: 19103566
[TBL] [Abstract][Full Text] [Related]
18. Degradation of vitamin D3 in a stressed formulation: the identification of esters of vitamin D3 formed by a transesterification with triglycerides.
Ballard JM; Zhu L; Nelson ED; Seburg RA
J Pharm Biomed Anal; 2007 Jan; 43(1):142-50. PubMed ID: 16901672
[TBL] [Abstract][Full Text] [Related]
19. Controlled release of saccharides from matrix tablets.
Mäki R; Suihko E; Korhonen O; Pitkänen H; Niemi R; Lehtonen M; Ketolainen J
Eur J Pharm Biopharm; 2006 Feb; 62(2):163-70. PubMed ID: 16343875
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.
Teijlingen Rv; Meijer J; Takusagawa S; Gelderen Mv; Beld Cv; Usui T
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 887-888():102-11. PubMed ID: 22317789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
